PRTA | tickerfilter.com

Fundamental analysis

24%

Profitability 0%

Dept financing 30%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.57%

1 Month

22.34%

3 Months

11.47%

6 Months

5.63%

1 Year

16.02%

2 Year

-49.32%

Key data

Stock price

$10.67

P/E Ratio

N/A

DAY RANGE

$10.48 - $10.78

EPS

-$4.53

52 WEEK RANGE

$4.32 - $11.69

52 WEEK CHANGE

$13.10

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

53.833 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

1.30

PUBLIC FLOAT

AVERAGE 10 VOLUME

$369,874

AVERAGE 30 VOLUME

$464,011

Company detail

CEO: Gene G. Kinney
Region: US
Website: prothena.com
Employees: 130
IPO year: 2012

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Prothena Corporation plc focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, is in clinical trials for Parkinson's disease; PRX004, which completed Phase I clinical trial.

PRTA - PROTHENA CORP PUBLIC LTD CO